Co-Diagnostics Inc. faces a potential delisting from the Nasdaq Capital Market due to non-compliance with Nasdaq’s minimum bid price requirement, which mandates a closing bid price of at least $1.00 per share. Despite implementing a 1-for-30 reverse stock split effective January 2, 2026, to increase its share price, the company failed to maintain the required bid price for the necessary period, prompting Nasdaq to issue a delisting notice. Co-Diagnostics plans to request a hearing to contest the delisting, but its shares are scheduled to be suspended from Nasdaq trading on January 14, 2026, and are expected to move to the OTC Market. The company may still seek reinstatement if it demonstrates compliance by maintaining the minimum bid price for 10 consecutive business days.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-001971), on January 13, 2026, and is solely responsible for the information contained therein.